PUBLISHER: BCC Research | PRODUCT CODE: 1416211
PUBLISHER: BCC Research | PRODUCT CODE: 1416211
The global market for biological therapeutic drugs is expected to increase from $452.9 billion in 2023 to $823.4 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.7% during the forecast period of 2023-2028.
Therapeutics and proteins market for biological therapeutic drugs is expected to increase from $248.5 billion in 2023 to $470.4 billion by the end of 2028, with a CAGR of 13.6% during the forecast period of 2023-2028.
Cell and gene therapy market for biological therapeutic drugs is expected to increase from $60.4 billion in 2023 to $119.4 billion by the end of 2028, with a CAGR of 14.6% during the forecast period of 2023-2028.
The current report offers a detailed picture of the biologics market.
This report highlights the current and future market potential for biologics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2028, as well as key market players.
This report details market shares for biologics based on product, source, application and geography. Based on product, the market is segmented into therapeutic proteins, cell and gene therapy, vaccines, and other segments. Based on application, the market is segmented into cancer, autoimmune conditions, aesthetics, eye disorders, and others. Based on source, the market is segmented into human, animal, micro-organism, fermented cell and others
Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2022 as the base year, with forecasts for 2023 through 2028. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.